ProMIS Neurosciences, Inc. (NASDAQ: PMN) is a Canadian biotechnology company headquartered in Toronto, Ontario, focused on developing novel therapeutics for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company's proprietary platform enables the generation of monoclonal antibodies that selectively target toxic oligomeric forms of disease proteins, offering a differentiated approach from traditional plaque-targeting strategies["@promis"].
Founded in 2007, ProMIS has built a leadership position in oligomer-selective antibody development, believing that soluble oligomers—rather than deposited plaques—represent the most toxic and disease-driving species in neurodegenerative conditions["@oligomer2020"].
Pipeline Overview
| Program | Target/Mechanism | Indication | Phase | Status | |---------|-----------------|------------|-------|--------| | PMN310 | Anti-Aβ oligomer mAb | Alzheimer's Disease | Phase 1 | Recruiting | | PMN350 | Anti-[tau](/proteins/tau) oligomer mAb | Alzheimer's Disease | Preclinical | Research | | PMN400 | Anti-[α-synuclein](/proteins/alpha-synuclein) mAb | Parkinson's Disease | Discovery | Research | | PMN310 | Anti-Aβ oligomer mAb | ALS | Preclinical | Research |
Alzheimer's Disease Programs
PMN310
PMN310 is a monoclonal antibody designed to selectively target toxic [amyloid-beta](/proteins/amyloid-beta) oligomers while sparing monomeric Aβ and amyloid plaques. This selectivity is achieved through ProMIS's proprietary conformational target technology, which identifies unique epitopes exposed only in oligomeric structures[@pmn2022].
Mechanism of Action:
Binds selectively to Aβ oligomers
Does not bind to Aβ monomers
Does not bind to amyloid plaques
Blocks oligomer-induced neurotoxicity
Promotes clearance of oligomeric species
Rationale:
The oligomer hypothesis proposes that soluble Aβ oligomers are the primary toxic species in Alzheimer's disease:
Oligomers are toxic: Correlate better with cognitive decline than plaques
Synaptic dysfunction: Oligomers directly impair synaptic function
Spread pathology: Oligomers propagate across brain regions
Therapeutic window: Selective targeting may improve safety
Clinical Development:
Phase 1: Currently recruiting healthy volunteers and AD patients
PMN350 is a tau oligomer-selective antibody in preclinical development. Like PMN310, it targets the toxic oligomeric form of tau while sparing normal tau monomers and neurofibrillary tangles[@pmn2023].
Features:
Selective for tau oligomers
Cross-reactive with multiple tau species
Potential for earlier intervention
Combination potential with PMN310
ALS Program
ProMIS is applying its oligomer-selective platform to ALS, where toxic protein aggregates also drive disease pathogenesis:
[TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates: Common in ALS
SOD1 aggregates: Familial ALS
Program: PMN310 for ALS (preclinical)
Technology Platform
ProMIS Oligomer-Selective Platform
The company's platform combines several technologies:
Selectively binds to Aβ oligomers (1000x vs monomers)
Protects [neurons](/entities/neurons) from oligomer-induced toxicity
Reduces synaptic loss in animal models
Improves cognitive performance
Favorable PK/PD properties
PMN350
Key preclinical findings:
Binds to tau oligomers from AD brain
Prevents tau oligomer propagation
Reduces tau pathology in models
Good brain penetration
Biomarker Strategy
ProMIS is developing biomarkers to support clinical development:
CSF biomarkers: Aβ oligomers, tau species
PET ligands: Oligomer-selective imaging
Target occupancy: Antibody-epitope engagement
Intellectual Property
The company maintains a strong patent portfolio:
Oligomer-selective antibody patents
Platform technology protection
Multiple therapeutic candidates
Global coverage
Financial Information
Market cap: ~$50 million (2024)
Cash runway: Through 2025
Funding: Public offerings, partnerships
Stock: Listed on NASDAQ
Key Personnel
Dr. Neil W. K. Cashman - Chief Scientific Officer and Co-Founder
Dr. James R. Kupiec - Chief Medical Officer
Eugene J. M. O. G. Williams - President and CEO
Danielle R. S. Brown - Chief Financial Officer
Partnerships
| Partner | Focus Area | Status | |---------|------------|--------| | University of Toronto | Research collaboration | Active | | Academic medical centers | Clinical development | Multiple | | CRO partners | Preclinical/clinical | Active |